Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Metabolic marker for rapidly diagnosing multiple myeloma and application

A technology for multiple myeloma and metabolic markers, which is applied in biological testing, phase effect characteristic measurement, color/spectral characteristic measurement, etc. It can solve the problems of long time consumption, lag, and low sensitivity of laboratory diagnosis, and achieve accurate results Reliable, highly sensitive results

Active Publication Date: 2022-08-09
CHINA JAPAN FRIENDSHIP HOSPITAL +1
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Since the clinical manifestations of MM are easily confused with other diseases, and the laboratory diagnosis of MM is generally low in sensitivity, time-consuming, expensive and lagging behind, it is urgent to develop a specific, rapid and economical method for the early diagnosis and curative effect evaluation of MM. , assessment or screening methods for disease progression

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Metabolic marker for rapidly diagnosing multiple myeloma and application
  • Metabolic marker for rapidly diagnosing multiple myeloma and application
  • Metabolic marker for rapidly diagnosing multiple myeloma and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Screening of metabolic markers between bone marrow tissues and bone marrow supernatants of patients with multiple myeloma and healthy individuals:

[0042] 1. Sample source:

[0043] Informed consent was signed with the participants and after approval by the Ethics Committee of Beijing Chaoyang Hospital Affiliated to Capital Medical University, bone marrow tissue and bone marrow supernatant samples were collected from 20 HC (healthy controls) and 16 MM patients. All participants were from Beijing Chaoyang Hospital Affiliated to Capital Medical University. All MM patients were diagnosed according to the IMWG standard. All MM patients were within 4 courses of chemotherapy, and the patients did not suffer from significant changes due to different courses of treatment. metabolic changes. HCs were matched for age and sex with MM patients to exclude metabolic differences due to sex and age. Bone marrow tissue and bone marrow supernatant were collected in the morning fasting...

Embodiment 2

[0067] Clinical analysis of specific cases:

[0068] (1) Sample collection:

[0069] Bone marrow tissue and bone marrow supernatant samples were collected from 20 HC (healthy controls) and 16 suspected MM patients. All participants were from Beijing Chaoyang Hospital affiliated to Capital Medical University. HCs were matched for age and sex with suspected MM patients to exclude metabolic differences due to sex and age. Blood collection time was in the early morning on an empty stomach. The fasting plasma samples of the subjects were collected and stored in a -80°C refrigerator for later use. All patients with suspected MM were diagnosed based on the following clinical diagnostic criteria.

[0070] 1. Symptoms and signs:

[0071] The most common symptoms and signs in patients with MM are associated with bone destruction, anemia, renal insufficiency, hypercalcemia, or infection. Common symptoms and manifestations of MM are shown in Table 4. The common ones are:

[0072] (...

Embodiment 3

[0118] Cell Validation Analysis:

[0119] The multiple myeloma cells H929 (purchased from the Cell Resource Center, Institute of Basic Medicine, Chinese Academy of Medical Sciences) used in this study were derived from the pleural effusion of a 62-year-old myeloma patient. H929 cells were cultured in 1640 medium and 10% FBS, centrifuged at 1000 rpm for 5 min, and counted. The 1640 medium of amino acid / tyrosine / tryptophan was cultured for 48 hours, and the cell viability was detected by CCK8. Image 6 It was shown that the survival rate of H929 cells was significantly decreased in the absence of phenylalanine, tyrosine, tryptophan, phenylalanine / tyrosine, and phenylalanine / tyrosine / tryptophan, respectively.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a metabolic marker for rapidly diagnosing multiple myeloma and application of the metabolic marker. The metabolic marker comprises one or more of phenylalanine, tyrosine and tryptophan. Compared with the prior art, the invention has the following advantages: the invention provides the metabolic marker for rapidly diagnosing multiple myeloma and the application thereof, the marker comes from one or a combination of more of bone marrow tissue and bone marrow supernatant metabolite of a patient, and comprises phenylalanine, tyrosine and tryptophan; the detection of the metabolic marker level can be effectively used for early clinical diagnosis of multiple myeloma diseases, the sensitivity is high, the method is rapid and convenient, the result is accurate and reliable, a basis can be provided for clinical decision making, meanwhile, a certain basis is provided for subsequent fundamental research and clinical research, and potential application and research values are achieved.

Description

technical field [0001] The invention relates to the technical field of biomedical detection, in particular to a metabolic marker for rapid diagnosis of multiple myeloma and its application. technical background [0002] Multiple myeloma (MM) is a clonal plasma cell tumor characterized by the secretion of monoclonal immunoglobulins. The disease is more common in middle-aged and elderly people, and it is more common in men than women. With the increasing problem of population aging in my country, the incidence of MM shows a significant upward trend. According to statistics, MM accounts for 1% of all cancers, 10% of malignant hematological tumors, and the median survival time is 3 to 5 years. MM patients usually have hypercalcemia, renal failure, anemia or osteolytic bone lesions. Due to the insidious onset and diverse clinical symptoms, misdiagnosis and missed diagnosis are often caused. The rate of misdiagnosis and missed diagnosis is close to 50%, which makes patients miss...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N30/02G01N30/04G01N30/90G01N30/72G01N24/08G01N21/41G01N21/33G01N21/359G01N21/3577G01N27/26G01N23/00G01N33/68
CPCG01N30/02G01N30/04G01N30/90G01N30/72G01N24/08G01N21/41G01N21/33G01N21/359G01N21/3577G01N27/26G01N23/00G01N33/6848G01N2030/047
Inventor 刘丽宏沈国林王晓雪宫丽丽刘爱军成虎程龙浩余江灵
Owner CHINA JAPAN FRIENDSHIP HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com